This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Scannon, P. J. Search for Related Content PubMed Articles by Scannon, P. J. Social Bookmarking                   What's this?

Recombinant 21 kDa N-terminal fragment of human bactericidal/permeability-increasing protein (rBPI21): progress in the clinic

Xoma Corporation, Berkeley, California, USA

rBPI₂₁ is a recombinant 193 amino acid protein derived from human BPI, a naturally occurring 456 amino acid host defense molecule made in neutrophils. rBPI₂₁ possesses multiple properties which include binding, clearing and neutralizing bacterial endotoxin, killing Gram-negative and Gram-positive bacteria, and enhancing bactericidal activity of a wide range of antibiotics. Neuprex ^®, the intravenous formulation of rBPI₂₁, has been evaluated in over 1700 patients to date in human volunteer studies and five Phase I/II indications, involving patients with meningococcemia, hemorrhagic trauma, complicated abdominal infections, partial liver resections and cystic fibrosis. The product has demonstrated an excellent safety profile and evidence of biological activity in every study completed to date. Thus far, two indications, meningococcemia and hemorrhagic trauma, have moved into Phase III trials.

Journal of Endotoxin Research, Vol. 5, No. 4, 209-212 (1999)
DOI: 10.1177/09680519990050040801


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?